Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias
Acta Neuropathologica · 2024
DOI: 10.1007/s00401-024-02712-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2024. Verfasst von Methasit Jaisa-Aad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Frontotemporal Dementia, Lewy Body Disease. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging, Real Colegio Complutense at Harvard University.
Themen: Demenz
Abstract (Originalsprache)
Reactive astrogliosis accompanies the two neuropathological hallmarks of Alzheimer’s disease (AD)—Aβ plaques and neurofibrillary tangles—and parallels neurodegeneration in AD and AD-related dementias (ADRD). Thus, there is growing interest in developing imaging and fluid biomarkers of reactive astrogliosis for AD/ADRD diagnosis and prognostication. Monoamine oxidase-B (MAO-B) is emerging as a target for PET imaging radiotracers of reactive astrogliosis. However, a thorough characterization of MAO-B expression in postmortem control and AD/ADRD brains is lacking. We sought to: (1) identify the primary cell type(s) expressing MAO-B in control and AD brains; (2) quantify MAO-B immunoreactivity in multiple brain regions of control and AD donors as a proxy for PET radiotracer uptake; (3) correlate MAO-B level with local AD neuropathological changes, reactive glia, and cortical atrophy; (4) determine whether the MAOB rs1799836 SNP genotype impacts MAO-B expression level; (5) compare MAO-B immunoreactivity across AD/ADRD, including Lewy body diseases (LBD) and frontotemporal lobar degenerations with tau (FTLD-Tau) and TDP-43 (FTLD-TDP). We found that MAO-B is mainly expressed by subpial and perivascular cortical astrocytes as well as by fibrous white matter astrocytes in control brains, whereas in AD brains, MAO-B is significantly upregulated by both cortical reactive astrocytes and white matter astrocytes across temporal, frontal, and occipital lobes. By contrast, MAO-B expression level was unchanged and lowest in cerebellum. Cortical MAO-B expression was independently associated with cortical atrophy and local measures of reactive astrocytes and microglia, and significantly increased in reactive astrocytes surrounding Thioflavin-S+ dense-core Aβ plaques. MAO-B expression was not affected by the MAOB rs1799836 SNP genotype. MAO-B expression was also significantly increased in the frontal cortex and white matter of donors with corticobasal degeneration, Pick’s disease, and FTLD-TDP, but not in LBD or progressive supranuclear palsy. These findings support ongoing efforts to develop MAO-B-based PET radiotracers to image reactive astrogliosis in AD/ADRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.
- MassGeneral Institute for Neurodegenerative Disease, 114 16th St., Charlestown, MA, 02129, USA.
- Harvard Medical School, Boston, MA, 02115, USA.
- Massachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.
- Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA. aserrano1@mgh.harvard.edu.
- MassGeneral Institute for Neurodegenerative Disease, 114 16th St., Charlestown, MA, 02129, USA. aserrano1@mgh.harvard.edu.
ORCID-Profile: Alberto Serrano-Pozo
Förderung
- NIA NIH HHS
- National Institute on Aging
- Real Colegio Complutense at Harvard University
- Prince Mahidol Award Youth Program
- Martin L. and Sylvia Seevak Hoffman Fellowship for Alzheimer's Research
- Karen Toffler Charitable Trust
- Harrison Gardner Jr. Innovation Award
Zitieren
APA
Jaisa-Aad, M., Muñoz-Castro, C., Healey, M. A., Hyman, B. T., & Serrano-Pozo, A. (2024). Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02712-2
Vancouver
Jaisa-Aad M, Muñoz-Castro C, Healey MA, Hyman BT, Serrano-Pozo A. Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias. Acta Neuropathologica. 2024. doi:10.1007/s00401-024-02712-2
BibTeX
@article{JaisaAad2024,
author = {Jaisa-Aad, Methasit and Muñoz-Castro, Clara and Healey, Molly A and Hyman, Bradley T and Serrano-Pozo, Alberto},
title = {Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias},
journal = {Acta Neuropathologica},
year = {2024},
doi = {10.1007/s00401-024-02712-2}
}
EUVIMED